GlassScriptPhysician profile
Gina M Cesaro
NPI 1861876849
$3,496.42
in general payments reported to CMS, 2019-2025
29 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $550 · 2023: $702 · 2024: $626 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $796.64 | 2025 | Rapiblyk |
| Actelion Pharmaceuticals US, INC. | $460.33 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $418.23 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $184.18 | 2022-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.19 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $147.95 | 2021-2025 | Farxiga |
| Abiomed | $135.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $130.67 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $112.70 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $108.70 | 2022-2025 | Verquvo, Winrevair |
| Pfizer INC. | $99.61 | 2022-2023 | |
| Abbott Laboratories | $88.54 | 2022-2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.24 | 2021-2025 | Jardiance |
| Baxter Healthcare | $73.61 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Endotronix, INC. | $57.26 | 2024-2025 | Cordella Pulomonary Artery Pressure Sensor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.02 | 2022-2024 | |
| Boston Scientific Corporation | $50.84 | 2024-2025 | Latitude Communicator Power Supply, Resonate El Icd Vr |
| United Therapeutics Corporation | $46.28 | 2024 | Remodulin, Orenitram |
| Cvrx, INC. | $43.54 | 2024 | Barostim Neo System |
| Irhythm Technologies, INC. | $37.18 | 2023 | Zio Xt Patch |
| Medtronic, INC. | $30.81 | 2025 | Affera Mapping System |
| Chiesi USA, INC. | $26.19 | 2021 | |
| Daxor Corporation | $20.88 | 2023 | Bva-100 |
| Scpharmaceuticals INC. | $20.24 | 2025 | |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Astellas Pharma US INC | $18.67 | 2025 | Cresemba |
| Genzyme Corporation | $17.70 | 2023 | |
| Impulse Dynamics (USA) INC. | $16.38 | 2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $14.88 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Cesaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.